Quick generic drug news for today. If you or a loved one suffers from hepatitis B, it’s bad news. Bristol-Myers Squibb has filed a lawsuit against Novartis to stop its generic version of hepatitis B drug Baraclude. Bristol-Myers filed the lawsuit last month against Novartis in U.S. District Court for the District of Delaware, accusing the generic drug company of infringing itsBaraclude patents.
Considering a thirty-day supply of brand-name Frova is currently running almost $1,000, a generic version of Baraclude could easily be a major savings for many hepatitis B patients. We have our fingers crossed on this one, and you can be sure we’ll keeping an eye on when a generic version of Baraclude will be able to hit the market!
- Generic Drug News: Pfizer Wins Suit To Block Generic Lyrica
- Generic Drug News: Novartis Sues to Block Generic Zometa, Generic Reclast
- Generic Drug News: Sandoz Files Suit to Release Generic Version of Diabetes Drug Prandin
- Generic Drug News: Endo Files Lawsuit to Block Generic Version of Migraine Drug Frova
- Generic Drug News: Pfizer Files Lawsuit to Block Generic Version of Pain Drug Lyrica